Ep 47: Pernilla Rönnholm, Laura Cigolot & patient groups. On-site pharmacies. Collateral phenotypes in M. tuberculosis.
In this episode, we bring you a double interview with two women deeply involved in patient advocacy and AMR. Tune in to hear the story of Pernilla Rönnholm, chair and founder of Mirakel, an association advocating for premature babies and their families, and the work that Laura Cigolot is doing within the AMR patient group, a cross-European initiative to bring awareness of AMR to many kinds of patients. We learn their perspectives, synergies, and what they hope for the road ahead.
In the news section, we cover an article looking into the potential financial incentives for antibiotic prescribing in Austria, and a study exploring the potential effects and uses of collateral phenotypes in Mycobacterium tuberculosis. We wish you a lovely month of April!
You can follow us and subscribe to our podcast to get new episodes directly in your preferred device and platform:
Relevant links:
- Pernilla Rönnholm's LinkedIn page.
- Premature Mirakel Association X account.
- Pernilla förlorade nyfödda dottern efter resistens. Swedish TV program about Pernilla's story.
- Official website of Health First Europe, and the AMR patient group website.
- AMR patient group on LinkedIn, and on Twitter.
Further Reading:
- Sweden: Pernilla’s 8-day old daughter died from sepsis – caused by resistant bacteria Klebsiella. Article by ReAct about Pernilla's story.
- Financial incentives and antibiotic prescribing patterns: Evidence from dispensing physicians in a public healthcare system. First article covered in the news section.
- The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis. Second article covered in the news.
If you have any comments and suggestions you can email us here, or tweet to us (@UAC_UU) using the hashtag #theAMRStudio.